Imatinib mesilate (GlivecNovartis Pharmaceuticals) is a novel therapy for the treatment of chronic myeloid leukaemia (CML). We evaluated the cost-effectiveness of imatinib (600 mg daily) when used for the treatment of patients in advanced stages of CML (accelerated phase and blast crisis) against conventiol therapies of combition chemotherapy (DAT) and palliative care in hospital or at home. A Markov model simulated the transitions of hypothetical patient cohorts and outcomes were modelled for 5 years from the start of treatment. Costs were estimated from the perspective of the UK tiol Health Service. Over 5 years, a patient in accelerated phase will, on average, accrue an additiol 2.09 QALYs with imatinib compared to conventiol therapies, while patients in blast crisis will accrue an additiol 0.58 quality-adjusted life-years (QALYs) with imatinib compared to conventiol therapies. The costs per additiol QALY gained from treatment with imatinib compared with conventiol therapies were 㲹 344 (accelerated phase) and 㴲 239 (blast crisis). The results were particularly sensitive to the price of imatinib, improvements in quality of life, and the duration of haematological responses. We conclude that treatment of CML with imatinib confers considerably greater survival and quality of life than conventiol treatments but at a cost.
Unless otherwise indicated, works by Griffith University Scholars are © Griffith University. For further details please refer to the University Intellectual Property Policy.